Truace
Subscribe

Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer

Importance The Decipher Prostate Genomic Classifier (GC) and ArteraAI Multimodal Artificial Intelligence (MMAI) platform are widely used prognostic tools for localized prostate cancer (PCa), yet no direct comparison has been performed within the same patient cohort. Methods We sought to evaluate the concordance and prognostic value of GC and MMAI across multi-institutional cohorts totaling 688 patients with localized and oligometastatic PCa. These included populations enriched for African American and East Asian…

By the Truvace desk2 min read1 sourcePeer-reviewedTRV-2026-1720· cite & verify
Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer
"Cytomegalovirus infection - Case 301" by Pulmonary Pathology is licensed under CC BY-SA 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/2.0/.

In brief

Researchers compared two widely used prognostic tools for localized prostate cancer, the Decipher genomic classifier and the Artera multimodal AI platform, within the same patients for the first time. The analysis covered 688 patients across several institutions, including groups enriched for African American and East Asian patients, with distant metastasis-free survival as the main endpoint.

The comparison matters because clinicians rely on such tools to judge risk, and until now there was no direct patient-level evidence on how they relate. The two scores were moderately correlated and both carried prognostic value, but results varied by cohort and specimen type, so the findings do not settle which tool is preferable.

Main points

  1. The study included 688 patients with localized and oligometastatic prostate cancer from multiple institutions.
  2. Cohorts were enriched for African American and East Asian patients.
  3. GC and MMAI scores were significantly correlated across multiple cohorts, though the correlation was described as moderate.
  4. Patients rated high-risk by both tools did qualitatively worse than others.
  5. Biopsy cohorts showed consistent discordance in signaling, metabolic, and DNA repair pathways.

The gain

In a direct same-cohort comparison, the Artera multimodal AI score predicted distant metastasis-free survival and in some cohorts added prognostic information beyond the Decipher genomic classifier.

The rundown

Both tools were stratified into risk groups according to whether the sample came from a biopsy or a radical prostatectomy. The primary outcome was distant metastasis-free survival, measured from diagnosis to last follow-up or event.

In the Moffitt radical prostatectomy, Moffitt biopsy, and NCCS cohorts, each score was prognostic on its own and after adjustment for clinical variables. In a model including both biomarkers and clinical variables, MMAI remained significant in Moffitt radical prostatectomy and was borderline in Moffitt biopsy.

A pathway analysis showed high concordance between the two tools for Moffitt radical prostatectomy and oligometastatic patients. Across both biopsy cohorts most biological pathways agreed, but signaling, metabolic, and DNA repair pathways were consistently discordant.

Sources

  1. Peer-reviewedClinical Cancer Research2026-10-08

The debate